Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development

References

• Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology. 2004 Mar;111(3):513–517.
   PubMed Web of Science ®Google Scholar
• Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004 Apr 21;291(15):1900–1901.
   PubMedGoogle Scholar
• Krishnan T, Ravindran RD, Murthy GV, et al. Prevalence of early and late age-related macular degeneration in India: the INDEYE study. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):701–707.
   PubMed Web of Science ®Google Scholar
• Gemmy Cheung CM, Li X, Cheng CY, et al. Prevalence and risk factors for age-related macular degeneration in Indians: a comparative study in Singapore and India. Am J Ophthalmol. 2013 Apr;155(4):764-773, 73 e1-3.
   Web of Science ®Google Scholar
• Carrion A, Etemad-Gilbertson B, Zhou J, et al. Characterization of the stoichiometry of human complement C5 binding to LFG316. Invest Ophthalmol Vis Sci. 2014 Apr;55(13):3432.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2007 Jan;114(1):92–98.
   PubMed Web of Science ®Google Scholar
• Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012 May;96(5):752–756.
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter R 3rd, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005 Apr 15; 308(5720):421–424.
   PubMed Web of Science ®Google Scholar
• Fagerness JA, Maller JB, Neale BM, et al. Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet. 2009 Jan;17(1):100–104.
   PubMed Web of Science ®Google Scholar
• Lambert NG, ElShelmani H, Singh MK, et al. Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res. 2016;54:64–102.
   PubMed Web of Science ®Google Scholar
• de Jong PT. Age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1474–1485.
   PubMed Web of Science ®Google Scholar
• Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008 Jun 12;358(24):2606–2617.
   PubMed Web of Science ®Google Scholar
• Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013 Apr;120(4):844–851.
   PubMed Web of Science ®Google Scholar
• Gehrs KM, Anderson DH, Johnson LV, et al. Age-related macular degeneration–emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450–471.
   PubMed Web of Science ®Google Scholar
• Seddon JM, Cote J, Davis N, et al. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003 Jun;121(6):785–792.
   PubMedGoogle Scholar
• Cashman SM, Ramo K, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PloS One. 2011 Apr 28;6(4):e19078.
   PubMed Web of Science ®Google Scholar
• Holz FG, Strauss EC, Schmitz-Valckenberg S, et al. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014 May;121(5):1079–1091.
   PubMed Web of Science ®Google Scholar
• Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008 Jan;115(1):116–126.
   PubMed Web of Science ®Google Scholar
• Bhisitkul RB, Desai SJ, Boyer DS, et al. Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP study). Ophthalmology. 2016 Jun;123(6):1269–1277.
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013 Nov;120(11):2292–2299.
   PubMed Web of Science ®Google Scholar
• Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000 Sep-Oct;45(2):115–134.
   PubMed Web of Science ®Google Scholar
• Khandhadia S, Lotery A. Oxidation and age-related macular degeneration: insights from molecular biology. Expert Rev Mol Med. 2010;12:e34.
   PubMed Web of Science ®Google Scholar
• Fanjul-Moles ML, Lopez-Riquelme GO. Relationship between oxidative stress, circadian rhythms, and AMD. Oxid Med Cell Longev. 2016;2016:7420637.
   PubMed Web of Science ®Google Scholar
• Johnson PT, Brown MN, Pulliam BC, et al. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4788–4795.
   PubMed Web of Science ®Google Scholar
• Newman AM, Gallo NB, Hancox LS, et al. Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks. Genome Med. 2012;4(2):16.
   PubMed Web of Science ®Google Scholar
• Strunnikova NV, Maminishkis A, Barb JJ, et al. Transcriptome analysis and molecular signature of human retinal pigment epithelium. Hum Mol Genet. 2010 Jun 15;19(12):2468–2486.
   PubMed Web of Science ®Google Scholar
• Kaneko H, Dridi S, Tarallo V, et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 2011 Mar 17;471(7338):325–330.
   PubMed Web of Science ®Google Scholar
• Tarallo V, Hirano Y, Gelfand BD, et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell. 2012 May 11;149(4):847–859.
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016 Feb;48(2):134–143.
   PubMed Web of Science ®Google Scholar
• Levy O, Calippe B, Lavalette S, et al. Apolipoprotein E promotes subretinal mononuclear phagocyte survival and chronic inflammation in age-related macular degeneration. EMBO Mol Med. 2015 Feb;7(2):211–226.
   PubMed Web of Science ®Google Scholar
• Parmeggiani F, Romano MR, Costagliola C, et al. Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm. 2012;2012:546786.
   PubMed Web of Science ®Google Scholar
• Bhutto IA, McLeod DS, Jing T, et al. Increased choroidal mast cells and their degranulation in age-related macular degeneration. Br J Ophthalmol. 2016 May;100(5):720–726.
   PubMed Web of Science ®Google Scholar
• Cherepanoff S, McMenamin P, Gillies MC, et al. Bruch’s membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol. 2010 Jul;94(7):918–925.
   PubMed Web of Science ®Google Scholar
• Nitsch D, Douglas I, Smeeth L, et al. Age-related macular degeneration and complement activation-related diseases: a population-based case-control study. Ophthalmology. 2008 Nov;115(11):1904–1910.
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005 Apr 15;308(5720):385–389.
   PubMed Web of Science ®Google Scholar
• Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227–7232.
   PubMed Web of Science ®Google Scholar
• Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin EyeResearch. 2010 Mar;29(2):95–112.
   PubMed Web of Science ®Google Scholar
• Tan PL, Bowes Rickman C, Katsanis N. AMD and the alternative complement pathway: genetics and functional implications. Hum Genomics. 2016;10(1):23.
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age-related macular degeneration. NatureGenetics. 2013 Apr;45(4):433-439, 39e1-2.
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005 Apr 15;308(5720):419–421.
   PubMed Web of Science ®Google Scholar
• Cao S, Ko A, Partanen M, et al. Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol. 2013 Dec;156(6):1176–1183.
   PubMed Web of Science ®Google Scholar
• Ebrahimi KB, Handa JT. Lipids, lipoproteins, and age-related macular degeneration. J Lipids. 2011;2011:802059.
   PubMedGoogle Scholar
• Doyle SL, Campbell M, Ozaki E, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med. 2012 May;18(5):791–798.
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005 May;80(5):595–606.
   PubMed Web of Science ®Google Scholar
• Schmitz-Valckenberg S, Fleckenstein M, Scholl HP, et al. Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol. 2009 Jan-Feb;54(1):96–117.
   PubMed Web of Science ®Google Scholar
• Bergmann M, Schutt F, Holz FG, et al. Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration. FASEB J. 2004 Mar;18(3):562–564.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006 Oct 19;443(7113):787–795.
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 2008 Jul;40(7):892–896.
   PubMed Web of Science ®Google Scholar
• Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal diseases. Curr Eye Res. 2011 Dec;36(12):1069–1077.
   PubMed Web of Science ®Google Scholar
• Feher J, Kovacs I, Artico M, et al. Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging. 2006 Jul;27(7):983–993.
   PubMed Web of Science ®Google Scholar
• Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16227–16232.
   PubMed Web of Science ®Google Scholar
• Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 2014 Jan;24(1):92–104.
   PubMed Web of Science ®Google Scholar
• Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013 May 9;368(19):1845–1846.
   PubMed Web of Science ®Google Scholar
• Mitter SK, Song C, Qi X, et al. Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. Autophagy. 2014;10(11):1989–2005.
   PubMed Web of Science ®Google Scholar
• Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14682–14687.
   PubMed Web of Science ®Google Scholar
• Johnson LV, Leitner WP, Staples MK, et al. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001 Dec;73(6):887–896.
   PubMed Web of Science ®Google Scholar
• Volz C, Pauly D. Antibody therapies and their challenges in the treatment of age-related macular degeneration. Eur J Pharm Biopharm. 2015 Sep;95(Pt B):158–172.
   PubMed Web of Science ®Google Scholar
• Hariri A, Nittala M, Sadda S. Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration. Am Acad Ophthalmol. 2015;122:407–413.
   Google Scholar
• Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014 Mar;121(3):693–701.
   PubMed Web of Science ®Google Scholar
• Garcia Filho CA, Yehoshua Z, Gregori G, et al. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2014 Jan-Feb;45(1):18–31.
   PubMed Web of Science ®Google Scholar
• Johnson L, Splawski I, Baker L, et al. Generation and characterization of CLG561: a fully-human, anti-properdin Fab for the treatment of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.. 2016;57(12):1116.
   Google Scholar
• Fluocinolone acetonide ophthalmic–Bausch & Lomb: fluocinolone acetonide envision TD implant. Drugs R D. 2005;6(2):116–119.
   PubMedGoogle Scholar
• Sadiq MA, Agarwal A, Soliman MK, et al. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. Expert Opin Drug Saf. 2015 Jul;14(7):1147–1156.
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013 Mar;33(3):498–507.
   PubMed Web of Science ®Google Scholar
• Schmitz-Valckenberg S, Mossner A, Fleckenstein M, et al. [Therapy approaches for geographic atrophy]. Ophthalmologe. 2010 Nov;107(11):1016–1019.
   PubMed Web of Science ®Google Scholar
• Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol. 1993 Oct;11(10):2036–2042.
   PubMed Web of Science ®Google Scholar
• Conley B, O’Shaughnessy J, Prindiville S, et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol. 2000 Jan;18(2):275–283.
   PubMed Web of Science ®Google Scholar
• Baglietto L, Torrisi R, Arena G, et al. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer. Cancer Detect Prev. 2000;24(4):369–375.
   PubMedGoogle Scholar
• Mariani L, Formelli F, De Palo G, et al. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability. Tumori. 1996 Sep-Oct;82(5):444–449.
   PubMed Web of Science ®Google Scholar
• Camerini T, Mariani L, De Palo G, et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol. 2001 Mar 15;19(6):1664–1670.
   PubMed Web of Science ®Google Scholar
• Quadro L, Blaner WS, Hamberger L, et al. The role of extrahepatic retinol binding protein in the mobilization of retinoid stores. J Lipid Res. 2004 Nov;45(11):1975–1982.
   PubMed Web of Science ®Google Scholar
• Vogel S, Piantedosi R, O’Byrne SM, et al. Retinol-binding protein-deficient mice: biochemical basis for impaired vision. Biochemistry. 2002 Dec 24;41(51):15360–15368.
   PubMed Web of Science ®Google Scholar
• Sogno I, Vene R, Sapienza C, et al. Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. Recent Results Cancer Res. 2009;181:71–76.
   PubMedGoogle Scholar
• Ribatti D, Raffaghello L, Marimpietri D, et al. Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett. 2003 Jul 18;197(1–2):181–184.
   PubMed Web of Science ®Google Scholar
• Kubota R, Boman NL, David R, et al. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina. 2012 Jan;32(1):183–188.
   PubMed Web of Science ®Google Scholar
• Kubota R, Al-Fayoumi S, Mallikaarjun S, et al. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina. 2014 Mar;34(3):603–609.
   PubMed Web of Science ®Google Scholar
• Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. 2008 Feb;14(2):194–198.
   PubMed Web of Science ®Google Scholar
• Petrukhin K. New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets. 2007 May;11(5):625–639.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jang YP, Chang S, et al. OT-674 suppresses photooxidative processes initiated by an RPE lipofuscin fluorophore. Photochem Photobiol. 2008 Jan-Feb;84(1):75–80.
   PubMed Web of Science ®Google Scholar
• Tanito M, Li F, Elliott MH, et al. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1900–1905.
   PubMed Web of Science ®Google Scholar
• Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6131–6139.
   PubMed Web of Science ®Google Scholar
• Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003 Apr;48(Suppl 1):S47–S51.
   PubMed Web of Science ®Google Scholar
• Ramirez C, Caceres-del-Carpio J, Chu J, et al. Brimonidine can prevent in vitro hydroquinone damage on retinal pigment epithelium cells and retinal Muller cells. J Ocul Pharmacol Ther. 2016 Mar;32(2):102–108.
   PubMed Web of Science ®Google Scholar
• Damico FM, Gasparin F, Scolari MR, et al. New approaches and potential treatments for dry age-related macular degeneration. Arq Bras Oftalmol. 2012 Jan-Feb;75(1):71–76.
   PubMed Web of Science ®Google Scholar
• Singer M. Advances in the management of macular degeneration. F1000Prime Rep. 2014;6:29.
   PubMedGoogle Scholar
• Ding JD, Lin J, Mace BE, et al. Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res. 2008 Feb;48(3):339–345.
   PubMed Web of Science ®Google Scholar
• Evans JB, Syed BA. New hope for dry AMD? Nat Rev Drug Discov. 2013 Jul;12(7):501–502.
   PubMed Web of Science ®Google Scholar
• Leyhe T, Andreasen N, Simeoni M, et al. Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study. Alzheimer’s Res Ther. 2014;6(2):19.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci. 2005 Mar;46(3):1033–1038.
   PubMed Web of Science ®Google Scholar
• Boltz A, Luksch A, Wimpissinger B, et al. Choroidal blood flow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4220–4225.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Hubschman J, Heilwel L, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379:713–720.
   PubMed Web of Science ®Google Scholar
• Song Won K, Park K-M, Kim H-J, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Rep. 2015;4:860–872.
   PubMed Web of Science ®Google Scholar
• Uchida N, Chen K, Dohse M, et al. Human neural stem cells induce functional myelination in mice with severe dysmyelination. Sci Transl Med. 2012 Oct 10;4(155):155ra36.
   Web of Science ®Google Scholar
• Gupta N, Henry RG, Strober J, et al. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med. 2012 Oct 10;4(155):155ra37.
   Web of Science ®Google Scholar
• Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013 Jun;11(6):643–652.
   PubMed Web of Science ®Google Scholar
• McGill TJ, Cottam B, Lu B, et al. Transplantation of human central nervous system stem cells – neuroprotection in retinal degeneration. Eur J Neurosci. 2012 Feb;35(3):468–477.
   PubMed Web of Science ®Google Scholar
• Cuenca N, Fernandez-Sanchez L, McGill TJ, et al. Phagocytosis of photoreceptor outer segments by transplanted human neural stem cells as a neuroprotective mechanism in retinal degeneration. Invest Ophthalmol Vis Sci. 2013 Oct;54(10):6745–6756.
   PubMed Web of Science ®Google Scholar
• Kim D, Song W. Membrane complement regulatory proteins. Clin Immunol. 2006;118:127–136.
   PubMed Web of Science ®Google Scholar